SULM – Schweizerische Union für Labormedizin | Union Suisse de Médecine de Laboratoire | Swiss Union of Laboratory Medicine

Sie sind hier | Vous êtes ici:

C Xu1 , Q Luo1 , P Dong1 , L Shen1

1Department of Clinical Laboratory, Xinhua Hospital, Shanghai Second Medical University, Shanghai 200092, P. R. China

Objective: To study the expression of ICAM-1 (CD54) on the surface of tumor cells and its correlation with the levels of soluble ICAM-1 in both plasma and peritoneal cavity fluid in patients with gastric carcinoma; and to evaluate ICAM-1’s significance in the metastasis of tumor and prognosis prediction for patients with gastric carcinoma(1-5).

Methods: 21 patients with gastric carcinoma and 10 normal controls were enrolled into this study. The expressions of ICAM-1 on tumor cell surface were measured with flow cytometry. Soluble ICAM-1 in plasma and peritoneal cavity fluid was detected with ELISA

Result: There was no significant difference in the expression of ICAM-1 on the surface of tumor cells between the patients of stage I (7.69±13.57 %) and stage II (10.96±14.50%) (p>0.05); but significant difference was noticed between the groups of stage II and stage III (39.89±34.03%) (p < 0.05), and between those with or without lymph nodes metastasis (32.94±31.54% vs 18.64±14.85%) (p < 0.05). The levels of sICAM-1 in plasma and peritoneal cavity fluid were also significantly different between stage I (212.27±26.33 ng/ml and 155.78±59.17 ng/ml) and stage II (323.45±86.85 ng/ml and 231.86±65.88 ng/ml) (p < 0.05), respectively. The sICAM-1 levels in patients with lymph nodes metastases (383.18±132.85 ng/ml in plasma and 268.54±80.76 ng/ml in celiac fluid ) were significantly higher than those without metastasis, which correlated well with the expression levels of ICAM-1 in tumor cell surface.

Summery and Conclusion: The expression of ICAM-1 on the surface of tumor cells and the levels of soluble ICAM-1 in plasma and celiac fluid in patients with gastric carcinoma are associated with TNM classification and the invasion of tumor, and ICAM-1 can be a prognostic factor for patients with gastric carcinoma.

Agenda

07. & 08.03.2019: Swiss eHealth Forum - Digitales Gesundheitswesen – Hope and > mehr

pipette

pipette 06/2018: Die Analyse der Darmflora | Analyse du microbiote

Aktuelle Ausgabe als E-Paper lesen

Jobs

17.12.2018: Cheflaboranten/in 80%, (HFR) Tafers